These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9041185)

  • 21. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
    Rudin CM; Yang Z; Schumaker LM; VanderWeele DJ; Newkirk K; Egorin MJ; Zuhowski EG; Cullen KJ
    Cancer Res; 2003 Jan; 63(2):312-8. PubMed ID: 12543781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
    Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ
    Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
    Parker RJ; Eastman A; Bostick-Bruton F; Reed E
    J Clin Invest; 1991 Mar; 87(3):772-7. PubMed ID: 1999494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
    Tanaka T; Masuda H; Naito M; Tamai H
    Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
    Hamelers IH; Staffhorst RW; Voortman J; de Kruijff B; Reedijk J; van Bergen en Henegouwen PM; de Kroon AI
    Clin Cancer Res; 2009 Feb; 15(4):1259-68. PubMed ID: 19228729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
    Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH
    Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
    Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
    Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
    Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
    Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
    Keshelava N; Seeger RC; Groshen S; Reynolds CP
    Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Establishment of human ovarian cancer cisplatin resistant cell line COC1/DDP and its mechanism of resistance].
    Zhou Y; Chen H; Yang Q
    Zhonghua Yi Xue Za Zhi; 1996 Sep; 76(9):680-3. PubMed ID: 9275551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines.
    Yang Z; Faustino PJ; Andrews PA; Monastra R; Rasmussen AA; Ellison CD; Cullen KJ
    Cancer Chemother Pharmacol; 2000; 46(4):255-62. PubMed ID: 11052622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Drug resistant mechanisms of platinum derivatives in a human cisplatin resistant ovarian cancer cell line].
    Nishiya I; Yoshizumi N; Fujiwara J; Kagabu T
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2871-81. PubMed ID: 3178236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
    Kumar A; Soprano DR; Parekh HK
    Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
    Li Q; Yu JJ; Mu C; Yunmbam MK; Slavsky D; Cross CL; Bostick-Bruton F; Reed E
    Anticancer Res; 2000; 20(2A):645-52. PubMed ID: 10810335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
    Belfi CA; Chatterjee S; Gosky DM; Berger SJ; Berger NA
    Biochem Biophys Res Commun; 1999 Apr; 257(2):361-8. PubMed ID: 10198218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
    Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.